Cann reiterated their positive rating on shares of Amgen, Inc. (NASDAQ:AMGN) in a research report report published on Wednesday morning. They currently have a $189.00 target price on the medical research company’s stock.
A number of other brokerages have also commented on AMGN. Mizuho set a $195.00 price target on Amgen and gave the company a buy rating in a research note on Friday, March 10th. Vetr lowered Amgen from a hold rating to a sell rating and set a $174.10 price target for the company. in a research note on Monday, March 13th. Oppenheimer Holdings Inc. reissued an outperform rating and set a $189.00 price target on shares of Amgen in a research note on Tuesday, March 14th. Piper Jaffray Companies reissued an overweight rating and set a $193.00 price target on shares of Amgen in a research note on Tuesday, March 14th. Finally, BMO Capital Markets reissued an outperform rating and set a $212.00 price target on shares of Amgen in a research note on Monday, March 6th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and twelve have given a buy rating to the stock. The company currently has an average rating of Hold and a consensus price target of $187.41.
Amgen (NASDAQ:AMGN) opened at 168.61 on Wednesday. Amgen has a 1-year low of $133.64 and a 1-year high of $184.21. The stock has a market capitalization of $124.17 billion, a PE ratio of 16.47 and a beta of 1.15. The stock’s 50 day moving average price is $171.88 and its 200 day moving average price is $159.85.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, February 2nd. The medical research company reported $2.89 EPS for the quarter, beating analysts’ consensus estimates of $2.79 by $0.10. Amgen had a return on equity of 29.42% and a net margin of 33.59%. The company earned $5.97 billion during the quarter, compared to analyst estimates of $5.75 billion. During the same period in the prior year, the company earned $2.61 earnings per share. The firm’s revenue was up 7.7% on a year-over-year basis. On average, equities research analysts predict that Amgen will post $12.31 earnings per share for the current fiscal year.
Your IP Address:
The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 8th. Stockholders of record on Wednesday, May 17th will be issued a $1.15 dividend. The ex-dividend date of this dividend is Monday, May 15th. This represents a $4.60 annualized dividend and a dividend yield of 2.73%. Amgen’s payout ratio is 44.92%.
Several large investors have recently modified their holdings of the company. Thomas J. Herzfeld Advisors Inc. purchased a new position in Amgen during the fourth quarter valued at approximately $102,000. New York Life Trust Co. increased its position in Amgen by 54.8% in the third quarter. New York Life Trust Co. now owns 624 shares of the medical research company’s stock valued at $104,000 after buying an additional 221 shares during the last quarter. Penserra Capital Management LLC increased its position in Amgen by 100.0% in the third quarter. Penserra Capital Management LLC now owns 684 shares of the medical research company’s stock valued at $114,000 after buying an additional 342 shares during the last quarter. Oakworth Capital Inc. increased its position in Amgen by 1.4% in the third quarter. Oakworth Capital Inc. now owns 711 shares of the medical research company’s stock valued at $119,000 after buying an additional 10 shares during the last quarter. Finally, Nelson Roberts Investment Advisors LLC purchased a new position in Amgen during the third quarter valued at approximately $123,000. Hedge funds and other institutional investors own 79.04% of the company’s stock.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/amgens-amgn-positive-rating-reiterated-at-cann/1708590.html
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.